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Background: The role of Th17 cells in colorectal tumorigenesis and development still remains unclear, despite the
fact that it has been established in the pathogenesis of autoimmune diseases.
Methods: We first analyzed Th17 cells and Treg cells using flow cytometry in the circulation of colorectal adenoma
(CRA) and colorectal carcinoma (CRC) patients and healthy controls, and the frequency of Th17 cells in peripheral
blood mononuclear cells (PBMCs) stimulated by anti-CD3 plus anti-CD28 and treated by IL-1β, IL-6, and TGF-β in
different concentrations. We then detected cytokines IL-1β, IL-6, IL-17A, IL-21, IL-23 or TGF-β by ELISA in sera and
supernatants from both normal and tumor tissues cultured ex vivo.
Results: It was found that the percentage of Th17 and Treg cells increased in the circulation of both CRA and CRC
patients; the increase of Th17 cells in the circulation occurred in early stages, whereas the increase of Treg cells in
the circulation and the increase of Th17 cells in tumor tissues occurred in advanced stages. The subsequent
cytokine profiling showed that, along CRC progression, IL-1β, IL-17A and IL-23 underwent a similar change, while
IL-6 in CRC exhibited an opposite change, with Th17 cells. In addition, high levels of TGF-β and IL-17A were
detected in tumor tissues rather than in normal mucosa. The in vitro experiment further demonstrated that IL-1β,
IL-6 or TGF-β modulated Th17 cell expansion in PBMC.
Conclusions: Our study reveals a unique change of Th17 cells, which is regulated possibly by IL-1β, IL-6 and TGF-β
in the progression of CRC.
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Colorectal cancer (CRC) is one of the leading causes of
cancer death in the world. Although the modality of
CRC has recently showed a slow reduction due to im-
provement in early detection and/or treatment in the
United States, it still keeps rising in China, especially in
the big metropolitan areas [1,2], thus still imposing a se-
vere threat to human health.
According to the adenoma-carcinoma sequence hy-
pothesis [3], CRC develops through a multistep process* Correspondence: ybao4356@gmail.com
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reproduction in any medium, provided the orfrom initially low-grade dysplastic adenoma to high-
grade dysplastic adenoma and ultimately to carcinoma.
Progression through this sequence is accompanied by
accumulation of tumorigenesis-related genetic mutations
and molecular changes [3,4]. The increasing evidence
shows that the balance in different CD4-positive T
lymphocyte subpopulations and cytokine networks are
also deregulated [4-6]. The changes of cytokine profiles
in the serum may be early events along the colorectal
adenoma-carcinoma sequence. Thus, they may serve as
important biological indices for the prognosis of CRC
[6-8]. In addition, subtyping of immune cells within
tumor tissues may be more effective in evaluating dis-
ease status than genetic changes [9-11].
Among different T lymphocyte subpopulations,
CD4+CD25+ T cells (Tregs) are vital in maintainingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mote tumor progression by inhibiting anti-cancer im-
mune responses [12,13]. Recent evidence suggests that
expression of IL-7 receptor-chain (also known as
CD127) on cell surface is inversely correlated with the
suppressive function of CD4+CD25hi Tregs and the ex-
pression of Foxp3, which is an Treg-expressing tran-
scription factor, so the Tregs can also be characterized
by CD4+CD25+CD127lo/- phenotype [14,15].
Recently, the Th17 cell, which is another CD4-positive
T lymphocyte subpopulation with its designation follow-
ing the feature of secreting IL-17, has been extensively
described for its involvement in several autoimmune dis-
eases and chronic inflammatory syndromes [16,17]. How-
ever, the role of Th17 cells in tumor immunity was less
studied as compared with Treg cells.
Among all cytokines, IL-1β, IL-6, IL-17, IL-21, IL-23
and TGF-β have been implicated in several autoimmune
diseases and inflammatory disorders. They are also
known to be able to modulate differentiation and devel-
opment of Th17 cells and Treg cells [17,18]. In mice,
low doses of TGF-β, together with IL-6 or IL-21 can ini-
tiate differentiation of naïve CD4+ T cells into the Th17
lineage, while high doses of TGF-β can drive formation
of the Treg lineage from naïve CD4+ T cell [19,20]. IL-23
is thought to be required in the maintenance of Th17
cell phenotype [17,19,21,22]. In humans, in addition to
IL-6, IL-21, TGF-β and IL-23,IL-1β was also found im-
portant in regulating Th17 cell differentiation [22-26].
Despite a great knowledge about differentiation and
function of Th17 cells in both mice and humans has
been accumulated, generation and regulation of Th17
cells in human cancer, especially in colorectal cancer,
still remain unclear. In this study, we investigated the
changes of Th17 and Treg cells, and the related cyto-
kines in the peripheral blood of patients with colorectal
adenoma (CRA) or CRC. We also detected the fre-
quency of Th17 cells and concentrations of the related
cytokines in both CRC tissues and the surrounding nor-
mal tissues. In addition, to determine which cytokines
play more dominant roles in the prevalence of Th17
cells, we subsequently assessed in an in vitro experiment
the effect of the related cytokines on the expansion of




Sixty six patients of 35 sporadic colorectal cancers and
31 colorectal adenomas, admitted in Beijing Shijitan
Hospital from June 2010 to July 2011, were enrolled in
this study. Both CRA and CRC patients were divided
into two groups based on disease progression. The find-
ings of tubular I and tubular II correspond to early stageand late stage, respectively, for CRA patients; the stage
I/II and stage III/IV were considered as early and late
stage, respectively for CRC patients. None of them
received radiotherapy, chemotherapy, or immunotherapy
before sample collection. The subjects with cancer his-
tory, autoimmune diseases, infectious diseases, inflam-
matory bowel diseases and familial polyposis were
excluded in this study. Patient profiles are summarized
in Table 1. Twenty four healthy donors without history
of tumor or other serious illnesses, in which 12 are fe-
male and 12 are male with mean age at 63 ranging from
42 to 83, were included as controls. The sample collec-
tion was performed with a written informed consent for
each subject and the study was conducted with the ap-
proval of the Shijitan Hospital’s ethics committee and in
compliance with the Helsinki Declaration.
Reagents
Collagenase type IV, hyaluronidase, deoxyribonuclease
type I, Ficoll-Hypaque and Percoll were from Sigma-
Aldrich. Recombinant IL-1β, IL-6 and TGF-β1 were
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controls were from BD Bioscience. Phorbol 12-myristate
13-acetate (PMA), ionomycin, Brefeldin A, FIX & PERM
Kit Reagent, IL-1β, IL-6, IL-17A, IL-21, IL-23, TGF-β
ELISA kit, and Anti-human CD3, CD28, CD8, CD127,
IL-17A and isotype controls were from eBioscience.
Tissue culture
Tissue culture was performed as previously described
[27]. Briefly, tumor tissue or normal mucosa was washed,
weighed, and then placed in a small tissue culture dish
containing RPMI-1640 medium supplemented with 10%
FBS and antibiotics. After incubation at 37°C with 5%
CO2 for 24 h and then centrifugation, the supernatant of
each sample was used for cytokine measurements.
Cell isolations
Normal infiltrating lymphocytes (NILs) and tumor infil-
trating lymphocytes (TILs) were isolated from freshly
resected surgical specimens by a method reported previ-
ously with some modifications [28]. In brief, the epithe-
lial layer was removed by stirring in 1 mM EDTA and
1 mM DTT for 1 h at 37°C. The tissue was minced, then
treated with a digestion solution containing 0.5 mg/ml
collagenase type IV, 1 mg/ml hyaluronidase and 0.1 mg/ml
deoxyribonuclease type I for 2 h with stirring at 37°C.
After digestion, the cells were washed and centrifuged
over a discontinuous Percoll gradient (75% and 40%).
PBMCs were isolated using Ficoll-Hypaque gradient. The
cells at the interface were harvested, washed and re-
suspended in RPMI-1640 complete medium. The cell via-
bility was determined by trypan blue exclusion.
Stimulation of PBMCs
The freshly isolated PBMCs (1 × 106 cells/well) from
health donors were stimulated in 4 μg/ml anti-CD3
monoclonal antibody-coated 96-well plate and 2 μg/ml
anti-CD28 antibody, and incubated for 84 h with RPMI-
1640 complete medium containing different cytokines
(IL-1β, 10 and 25 ng/ml; IL-6, 25 and 50 ng/ml; TGF-β1,
5 and 0.5 ng/ml ) alone or in combination. For intracel-
lular cytokine staining, the purified PBMCs, NILs and
TILs were stimulated for 5 h in RPMI complete medium
with 50 ng/ml PMA and 1 μg/ml ionomycin in the pres-
ence of 10 μg/ml Brefeldin A.
Cytokine measurements
Concentrations of cytokines IL-1β, IL-6, IL-17A, IL-21,
IL-23 or TGF-β in sera, supernatants of tissue, and
cell cultures of the stimulated PBMCs were measured
using a specific ELISA kit. Results of the cytokine con-
centrations in the supernatant of tissue cultures are
expressed as pg/mg of tissue weight/ml of culture
medium.Flow cytometry assays
Surface protein staining of PBMCs, NILs and TILs were
performed at room temperature for 20 min using the
following antibodies: the PE-Cy5-conjugated anti-CD3
and FITC-conjugated anti-CD8 were used for stain-
ing Th17 cells; the FITC-conjugated anti-CD4 and
PE-CyTM7-conjugated anti-CD25 and PE-conjugated
anti-CD127 were used for Treg Cells. Before staining with
the PE-conjugated anti-IL-17A, cells were washed, fixed
and permeated using FIX & PERM Kit Reagent following
the manufacturer’s instructions. The isotype control of
each dye-conjugated antibody was used to correct com-
pensation and confirm antibody specificity. The stained
cells were analyzed by a Calibur flow cytometer equipped
with CellQuest software.
Statistical analysis
Data were analyzed by SPSS statistical software (version
16, SPSS Inc., Chicago, IL) using Student's t test or one-way
ANOVA and the Mann–Whitney U test or the Kruskal-
Wallis test. A level of P < 0.05 was considered statistically
significant.
Results
Percentage of the circulating Th17 cells in CRA and CRC
patients
To investigate the changes of Th17 cells in the progres-
sion of CRC, we first measured Th17 cells in the PBMCs
of CRA and CRC patients and healthy controls. The
analysis for the percentage of Th17 cell in total CD4+T
cells in patients and controls were shown in Figure 1.
The percentage of Th17 cells was significantly increased
in both CRA (median, 1.2%; 25th to 75th percentiles,
0.6% to 1.6%; P = 0.028) and CRC patients (1.7%; 1.3%
to 2.4%; P < 0.001) as compared with healthy controls
(0.7%; 0.4% to 1.2%). In addition, the percentage of Th17
cells in CRC patients was significantly higher than that
in CRA patients (P = 0.001). Following disease progres-
sion, we observed that the percentage of Th17 cells was
decreased in advanced stages of both CRAs and CRCs in
comparison with early stage of each disease (0.8%; 0.5%
to 1.3% vs 1.4%; 0.6% to 2.0%, P = 0.014; 1.4%; 1.3% to
1.9% vs 2.2%; 1.6% to 3.8%, P = 0.025). Although both in
advanced stages, CRC patients showed a higher percent-
age of Th17 cells than CRA patients (P = 0.002).
Distribution of Th17 cells in NILs and TILs
Subsequently, we found that percentage of Th17 cells in
TILs (1.8%; 0.8% to 2.8%) was increased as compared
with NILs (1.7%; 0.8% to 2.6%) or PBMCs (1.6%; 1.2% to
2.5%), but did not show any statistical significance. How-
ever, the percentage of Th17 cells in the TILs of patients
in advanced stages was significantly higher than that in
Figure 1 The population of Th17 cells in PBMCs , NILs and TILs. A. The CD3+CD8- T (CD4+ T) cells were gated after lymphocytes gating.
B. Proportions of Th17 cells to CD4+ T subsets from the representative PBMC, NIL and TIL were indicated. Percentages of Th17 cells are shown in
CRA (n = 31), CRC (n = 35), and healthy donors (n = 24) (C); in patients at early (CRA, n = 19; CRC n = 14) and advanced (CRA, n = 12; CRC
n = 21) stages (D); in PBMCs (n = 20), NILs (n = 20) and TILs (n = 20) from the same CRC patients (E), and in PBMCs and TILs from the same
patients at early (n = 9) and advanced (n = 11) stages (F). Each datum point represents an individual sample. The horizontal line represents
median values for each group.
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P = 0.03) (Figure 1).
Percentage of the circulating Tregs in CRA and CRC
patients
Observations of Tregs in this study showed that percent-
age of Tregs was significantly increased in CRA and
CRC patients (3.6%; 3.0% to 5.3%, P = 0.002; 4.4%; 2.6%
to 5.9%, P = 0.002) as compared with healthy controls
(2.8%; 2.2% to 3.6%). Although the percentage of Tregs
was higher in CRC patients than that in CRA patients,
no significant difference was observed between them(P = 0.36). In contrast to Th17 cells, the percentages of
circulating Tregs were significantly higher in advanced
stages than in early stages of both CRA and CRC
patients (4.4%; 3.4% to 6.0% vs 3.5%; 2.5% to 4.7%, P =
0.047; 5.4%; 4.1% to 7.0% vs 2.5%; 1.2% to 3.8%, P =
0.003) (Figure 2).
Seral concentrations of IL-1β, IL-6, IL-17A and IL-23 of
CRA and CRC patients
To investigate whether the changes of Th17 cells were
accompanied by cytokine alterations, we then measured
seral concentrations of IL-1β, IL-6, IL-17A and IL-23 in
Figure 2 Population of the Treg cells in PBMCs. A. CD4+CD25+ T cells were gated after lymphocytes gating and the calculated numbers of
CD4+CD25+CD127- T cells in CD4+ T cells were indicated in the representative control, CRA and CRC patient. Percentages of Treg cells are shown
in CRA (n = 31), CRC (n = 31), and healthy controls (n = 24) (B), and in patients at early (CRA, n = 19; CRC n = 11) and advanced (CRA, n = 12;
CRC n = 20) stages (C). Each datum point represents an individual sample. The horizontal line represents median values for each group.
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shown in Figure 3, concentrations of IL-17A and IL-23
were higher in CRA patients (IL-17A: 6.4 ± 0.8 pg/ml,
P = 0.242; IL-23: 34.6 ± 4.4 pg/ml, P = 0.004 ) and
highest in CRC patients (16.1 ± 2.5 pg/ml, P < 0.001;
55.2 ± 5.5 pg/ml, P < 0.001) as compared with healthy
controls (5.0 ± 0.8 pg/ml; 18.6 ± 2.7 pg/ml). However,
IL-1β and IL-6 were higher in CRC (IL-1β: 7.3 ±
0.6 pg/ml, P < 0.001; IL-6: 25.6 ± 2.6 pg/ml, P = 0.001)
but highest in CRA (9.3 ± 0.6 pg/ml, P < 0.001; 33.9 ±
2.1 pg/ml, P < 0.001 ) as compared with healthy con-
trols (4.6 ± 0.2 pg/ml; 11.2 ± 2.3 pg/ml). Following dis-
ease progression, we further found that IL-1β, IL-17A
and IL-23 were significantly higher in early stages than in
advanced stages of CRA patients (IL-1β: 11.4 ± 0.6 pg/ml
vs 6.2 ± 0.4 pg/ml, P < 0.001; IL-17A : 7.6 ± 1.2 pg/ml vs
4.7 ± 0.5 pg/ml, P = 0.038; IL-23: 42.8 ± 6.5 pg/ml vs
22.2 ± 3.1 pg/ml, P = 0.015) and CRC patients (9.3 ±
1.2 pg/ml vs 6.0 ± 0.5 pg/ml, P = 0.022; 25.1 ± 3.7 pg/ml
vs 10.2 ± 2.8 pg/ml, P = 0.002; 68.4 ± 9.5 pg/ml vs 46.5 ±
6.2 pg/ml, P = 0.043). Regardless of disease stages, IL-
17A and IL-23 exhibited higher levels in CRC patients
than in CRA patients (IL-17A: P < 0.001 or P = 0.068;
IL-23: P = 0.029 or P = 0.002), whereas IL-6 concentra-
tion was increased in the advanced CRCs (28.3 ±
3.3 pg/ml vs 21.7 ± 2.6 pg/ml, P = 0.154) but decreasedin the advanced CRAs (27.7 ± 3.1 pg/ml vs 38.0 ±
2.4 pg/ml, P = 0.013) as compared with early stage of
each disease.
Concentrations of IL-1β, IL-6, IL-17A, IL-21, IL-23 and TGF-β
released from the cultured tissues
To reveal cytokine changes in tissues, we then measured
concentrations of IL-1β, IL-6, IL-17A, IL-21, IL-23 and
TGF-β in the supernatants of the cultured normal colo-
rectal mucosa and CRC tissues. As shown in Figure 4, in
comparison with normal mucosa, the tumor tissues
released significantly higher amounts of IL-17A (224.2 ±
34.2 pg/mg tissue vs 148.3 ± 14.0 pg/mg tissue, P =
0.047) and TGF-β (1311.5 ± 157.6 pg/mg tissue vs 649.5 ±
75.6 pg/mg tissue, P = 0.001), but not IL-1β (P = 0.144),
IL-21(P = 0.262), IL-23 (P = 0.489) and IL-6 (P = 0.513).
However, we found that the tissues of the advanced CRC
released significantly higher amount of IL-1β (2305.8 ±
618.8 pg/mg tissue vs 822.2 ± 240.9 pg/mg tissue, P =
0.044) than the tissues of the early CRC, while the re-
lease of IL-6 (4365.9 ± 317.1 pg/mg tissue vs 3026.2 ±
506.3 pg/mg tissue, P = 0.048) was significantly higher
from the early CRCs than from the advanced CRCs. But
IL-17A, IL-23, IL-21 and TGF-β released from the CRC
tissues did not show a significant stage-associated
change.
Figure 3 Cytokine measurement in serum. Concentrations of IL-1β (A),IL-6 (B),IL-17A (C) and IL-23 (D) in the serum of health donors (n = 16)
and patients with CRA (n = 30; early stage, n = 18; advanced stage, n = 12) and CRC (n = 35; early stage, n = 14; advanced stage, n = 21) were
measured by ELISA. The cytokine concentration (pg/ml) is expressed as mean ± SEM.
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cells in PBMCs
To further determine whether the changes of Th17 cells
were the consequence of the alteration of IL-1β, IL-6and TGF-β, we investigated the effects of IL-1β, IL-6
and TGF-β on the expansion of Th17 cells in PBMCs.
The medium from PBMCs stimulated by anti-CD3 plus
anti-CD28 with no cytokine treatment served as a
Figure 4 Cytokine measurement in the supernatants of tissue culture. Concentrations of IL-1β (Α),IL-6 (B),IL-17A (C), TGF-β (D), IL-23 (E),IL-21
(F) in the supernatant of colorectal normal tissues (n = 20) and CRC tissues(n = 20; early stage, n = 9; advanced stage, n = 11) of the same CRC
patients were measured by ELISA. The cytokine concentration (pg/mg tissue) is expressed as mean ± SEM.
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or 5 ng/ml TGF-β alone reduced the number of Th17
cells in comparison with 25 ng/ml IL-6 (P = 0.037) or
0.5 ng/ml TGF-β (0.5 ng/ml) (P = 0.038) alone. How-
ever, the combination of IL-6hi (50 ng/ml) plus TGF-βhi
(5 ng/ml) significantly increased Th17 cell numbers as
compared with IL-6 hi alone (P < 0.001). The high (hi)
or low (lo) concentration of each cytokine was arbitrarily
defined based on the significant effect of each cytokine
on Th17 cell expansion. IL-1βhi (25 ng/ml) increased the
number of Th17 cells as compared with no cytokine
control (P = 0.037) or IL-1βlo (10 ng/ml) (P = 0.037),
but IL-1βhi plus TGF-βhi slightly decreased the number
of Th17 cells as compared with IL-1βhi (P = 0.522). In
addition, the changes of IL-17A level in the supernatantsshowed a similar trend with the changes of Th17 cell
number, but did not show any statistical significance
among different cytokine groups (data not shown).
Discussion
The present study provided for the first time compre-
hensive data on the changes of Th17/Treg cells and
cytokines IL-1β,IL-6,IL-17A,IL-21,IL-23 and TGF-β in
the development and progression of CRC. It demon-
strated in both CRA and CRC patients an increase of
circulating Th17 cells in early stages and an increase of
circulating Treg cells in advanced stages, and an increase
of tumor infiltrating Th17 cells in advanced CRC tissues.
The changes of Th17 cells along disease progression
were accompanied by alterations of IL-1β, IL-6, IL-17A,
Figure 5 Percentages of Th17 cell in the stimulated PBMCs in
the presence of different cytokines. Percentages of Th17 cells
over the anti-CD3/CD28-stimulated PBMCs of the healthy donors
following treatment with IL-1βhi (25 ng/ml), IL-1βlo (10 ng/ml), IL-6hi
(50 ng/ml), IL-6lo (25 ng/ml), TGF-βhi (5 ng/ml) and TGF-βlo (0.5 ng/ml)
are indicated. Results are expressed as mean ± SEM from six
independent experiments. * P < 0.05, ** P < 0.01.
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studies further supported that the expansion of the Th17
cells were regulated by IL-1β, IL-6 and TGF-β in different
combinations and/or concentrations.
Previously, the elevated percentage of Th17 cells were
detected in blood, bone marrow, and spleen in mouse
tumor models, and in peripheral blood, malignant asci-
tes and tumor tissues in patients of advanced ovarian,
pancreatic, renal cell carcinomas, melanoma, and breast
and colon cancers [29,30]. In gastric cancer, there were
elevations of Th17 cells in the peripheral blood as well
as tumor-draining lymph nodes, both of which were
associated with clinical stages of cancer development
[31]. However, in ovarian cancer patients, the percentage
of Th17 cells appeared higher in tumor but lower in per-
ipheral blood or PBMCs and tumor-draining lymph
nodes [32,33]. Our data showed that the frequency of
Th17 cells was markedly increased in the circulation of
both CRA and CRC patients, but became significantly
lower as the diseases progressed to the advanced stages.
Moreover, our observations were consistent with an ani-
mal study, in which the Th17 cells were increased in
tumor tissues as disease progressed and reached to a
maximal level in advanced tumors [29].
A previous study showed that IL-1β, IL-6 and TGF-β
were involved in differentiation and expansion of the
Th17 cells in ovarian cancers; IL-1β and IL-6 promoted,
whereas TGF-β inhibited, Th17 cell expansion [32]. Ourresults showed that the changes in Th17 cell number
along disease progression were accompanied by varia-
tions of IL-1β, IL-6 and IL-23 levels, suggesting the asso-
ciation of these cytokines with Th17 cell expansion.
Given that the variation of cytokine levels, as seen in
TGF-β, did not consistently follow the change of Th17
cells, we speculated the existence of an optimal level of
these cytokines in regulating Th17 cell expansion. In-
deed, we found that TGF-βlo, IL-6 lo or IL-1βhi increased
Th17 cell number in PBMCs. However,IL-6hi plus TGF-
βhi unexpectedly promoted Th17 cell expansion, sug-
gesting that a complex cytokine context, rather than the
change of individual cytokines, is more likely involved in
regulating Th17 cells. In the early stages, accumulation
of Th17 cells in tumor tissues may be supported by high
concentrations of TGF-β and IL-6. However, following
tumor progression, high level of IL-1β, and possibly IL-
23 as well, with the reduced levels of IL-6 and TGF-β
may become supporting cytokine milieu for the expan-
sion of Th17 cells in tumor tissues.
In this study, we detected the reduced level of IL-1β
and increased frequency of Th17 cells in the circulation
of CRCs as compared with that of CRAs. Since the IL-
23 level is commonly elevated in the circulation of CRC
patients, we speculated that IL-23 or other unknown fac-
tors, rather than IL-1β, may be more responsible for the
expansion of Th17 cells in the circulation of CRC
patients. Nevertheless, new studies are needed to test
this hypothesis.
Previous reports showed that IL-21 promoted differ-
entiation of human naïve CD4+T cells into Th17 cells
[23]. IL-21 was found essential in patients of inflam-
matory bowel diseases (IBD) in promoting IL-17 pro-
duction in anti-CD3/CD28-stimulated LPMCs, whereas
IL-1β, IL-6, IL-23 and TGF-β exerted no effects [34].
However, our observation showed no significant differ-
ence in IL-21 level between normal tissues and tumor
tissues or between early and advanced CRC tissues.
This discrepancy may be interpreted by the difference
in immunological mechanisms for regulating Th17 cells
between IBD and cancer.
Previous studies showed that Th17 cells can be
recruited into tumor microenvironment from the circu-
lation [30]. These findings are supportive at least in part
to our observations that, in advanced CRCs, the Th17
cells became reduced in the circulation but increased in
tumor tissues. We cannot of course exclude another
possibility that the Th17 cells were converted into Treg
cells during tumor progression. The emerging evidence
suggested that Th17 cells are of functional plasticity and
can be converted into Treg cells in vitro and these cells
cannot change back to Th17 cells even under the highly
favorable conditions [35,36]. Nevertheless, new studies
to test these two possibilities are warranted.
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Our study uncovers a unique change of Th17 cells and
Treg cells and cytokines IL-1β, IL-6, IL-17A, and IL-23
along the progression of CRC. It further reveals that the
Th17 cells are subjected to a complicated modulation by
IL-1β,IL-6 and TGF-β. Clearly, the current study
advances our understanding of the immunological
mechanisms for CRC progression. It may thus help iden-
tify novel prognostic and therapeutic strategies for this
disease.
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